Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cytochrome P-450 CYP3A | 9 | 2021 | 88 | 2.910 |
Why?
|
Glucuronosyltransferase | 9 | 2022 | 105 | 2.750 |
Why?
|
Camptothecin | 5 | 2022 | 526 | 2.240 |
Why?
|
Antineoplastic Agents, Phytogenic | 5 | 2022 | 873 | 1.990 |
Why?
|
Liver | 10 | 2021 | 2915 | 1.530 |
Why?
|
Toll-Like Receptor 4 | 4 | 2022 | 206 | 1.430 |
Why?
|
Hepatocytes | 6 | 2021 | 345 | 1.210 |
Why?
|
Inactivation, Metabolic | 4 | 2018 | 42 | 1.060 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 4 | 2018 | 294 | 1.060 |
Why?
|
Lipopolysaccharides | 6 | 2019 | 580 | 1.030 |
Why?
|
Enzymes | 2 | 2017 | 67 | 0.940 |
Why?
|
Toll-Like Receptor 2 | 3 | 2022 | 94 | 0.880 |
Why?
|
Membrane Transport Proteins | 3 | 2013 | 237 | 0.850 |
Why?
|
Gene Expression Regulation | 5 | 2019 | 3949 | 0.840 |
Why?
|
Receptors, Steroid | 4 | 2018 | 289 | 0.800 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2022 | 152 | 0.760 |
Why?
|
Diarrhea | 5 | 2022 | 689 | 0.690 |
Why?
|
Receptors, Interleukin-1 | 2 | 2011 | 96 | 0.670 |
Why?
|
Cytochrome P-450 Enzyme System | 3 | 2015 | 205 | 0.660 |
Why?
|
Paclitaxel | 2 | 2017 | 2060 | 0.650 |
Why?
|
Multidrug Resistance-Associated Proteins | 2 | 2017 | 84 | 0.650 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2020 | 197 | 0.640 |
Why?
|
Toxicity Tests | 1 | 2018 | 52 | 0.620 |
Why?
|
Rifampin | 2 | 2018 | 205 | 0.620 |
Why?
|
Membrane Proteins | 5 | 2019 | 2844 | 0.600 |
Why?
|
Inflammation | 4 | 2022 | 2479 | 0.570 |
Why?
|
Pharmaceutical Preparations | 2 | 2021 | 152 | 0.540 |
Why?
|
Teichoic Acids | 3 | 2013 | 13 | 0.540 |
Why?
|
Glucuronates | 1 | 2015 | 9 | 0.530 |
Why?
|
Toll-Like Receptor 3 | 1 | 2015 | 25 | 0.520 |
Why?
|
Gastrointestinal Diseases | 1 | 2020 | 600 | 0.510 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2015 | 95 | 0.510 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2015 | 75 | 0.500 |
Why?
|
Membrane Glycoproteins | 2 | 2011 | 1061 | 0.480 |
Why?
|
Cytokines | 5 | 2017 | 2751 | 0.470 |
Why?
|
Mice, Inbred C57BL | 9 | 2021 | 7039 | 0.460 |
Why?
|
Animals | 23 | 2022 | 59528 | 0.440 |
Why?
|
Biological Products | 1 | 2017 | 312 | 0.430 |
Why?
|
Carboxylesterase | 3 | 2018 | 33 | 0.430 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 3 | 2013 | 582 | 0.430 |
Why?
|
Pharmacokinetics | 1 | 2012 | 41 | 0.430 |
Why?
|
Toll-Like Receptors | 1 | 2013 | 167 | 0.420 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2016 | 1548 | 0.410 |
Why?
|
Obesity | 3 | 2015 | 2907 | 0.410 |
Why?
|
Biological Transport | 1 | 2013 | 581 | 0.410 |
Why?
|
Mice | 15 | 2022 | 34706 | 0.380 |
Why?
|
Chlorpromazine | 1 | 2010 | 17 | 0.360 |
Why?
|
Diet | 1 | 2018 | 1457 | 0.360 |
Why?
|
Transcriptome | 1 | 2019 | 1923 | 0.360 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2015 | 676 | 0.350 |
Why?
|
Dietary Fats | 1 | 2011 | 339 | 0.330 |
Why?
|
Acetaminophen | 1 | 2010 | 122 | 0.320 |
Why?
|
Gene Expression | 2 | 2013 | 3467 | 0.310 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2016 | 8939 | 0.310 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 5104 | 0.290 |
Why?
|
Drug Interactions | 3 | 2017 | 562 | 0.280 |
Why?
|
Glucuronidase | 2 | 2018 | 46 | 0.280 |
Why?
|
Hep G2 Cells | 2 | 2018 | 147 | 0.280 |
Why?
|
Enzyme Induction | 2 | 2018 | 238 | 0.280 |
Why?
|
Cells, Cultured | 5 | 2021 | 5454 | 0.280 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 14438 | 0.260 |
Why?
|
Transcription Factor TFIIA | 1 | 2004 | 2 | 0.240 |
Why?
|
RNA, Ribosomal, 5S | 1 | 2004 | 12 | 0.240 |
Why?
|
Down-Regulation | 3 | 2017 | 2075 | 0.240 |
Why?
|
Fatty Liver | 2 | 2018 | 245 | 0.220 |
Why?
|
Xenopus | 1 | 2004 | 220 | 0.220 |
Why?
|
Uridine Diphosphate | 1 | 2022 | 8 | 0.210 |
Why?
|
Signal Transduction | 7 | 2020 | 11940 | 0.210 |
Why?
|
Biliary Tract | 2 | 2020 | 36 | 0.210 |
Why?
|
Mice, Mutant Strains | 2 | 2017 | 629 | 0.200 |
Why?
|
Area Under Curve | 2 | 2020 | 710 | 0.190 |
Why?
|
Male | 14 | 2021 | 124154 | 0.180 |
Why?
|
Half-Life | 1 | 2019 | 255 | 0.170 |
Why?
|
Drugs, Chinese Herbal | 1 | 2019 | 62 | 0.160 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2019 | 545 | 0.150 |
Why?
|
Retinoid X Receptor alpha | 2 | 2008 | 39 | 0.150 |
Why?
|
Tandem Mass Spectrometry | 1 | 2019 | 382 | 0.140 |
Why?
|
Mice, Inbred C3H | 1 | 2017 | 379 | 0.140 |
Why?
|
ROC Curve | 1 | 2019 | 1187 | 0.140 |
Why?
|
Poly I-C | 1 | 2015 | 29 | 0.130 |
Why?
|
Administration, Oral | 1 | 2019 | 1557 | 0.130 |
Why?
|
Intestines | 1 | 2020 | 680 | 0.130 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2022 | 1446 | 0.130 |
Why?
|
Enzyme Activation | 1 | 2019 | 1774 | 0.130 |
Why?
|
Models, Theoretical | 1 | 2019 | 765 | 0.130 |
Why?
|
In Vitro Techniques | 3 | 2008 | 1576 | 0.130 |
Why?
|
Quinolines | 1 | 2019 | 395 | 0.130 |
Why?
|
Metabolome | 1 | 2018 | 355 | 0.130 |
Why?
|
Drug Monitoring | 1 | 2017 | 333 | 0.130 |
Why?
|
Liver Neoplasms | 1 | 2012 | 4632 | 0.120 |
Why?
|
Luciferases | 1 | 2016 | 442 | 0.120 |
Why?
|
DNA, Complementary | 1 | 2016 | 863 | 0.120 |
Why?
|
RNA, Messenger | 2 | 2015 | 6048 | 0.120 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2017 | 595 | 0.110 |
Why?
|
Genes, Reporter | 1 | 2016 | 785 | 0.110 |
Why?
|
Body Weight | 1 | 2018 | 1289 | 0.110 |
Why?
|
Busulfan | 1 | 2017 | 776 | 0.110 |
Why?
|
Isoenzymes | 1 | 2015 | 618 | 0.110 |
Why?
|
Intestinal Mucosa | 1 | 2019 | 1065 | 0.110 |
Why?
|
Computational Biology | 1 | 2019 | 1249 | 0.110 |
Why?
|
Transfection | 2 | 2016 | 2931 | 0.100 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2016 | 1193 | 0.100 |
Why?
|
RNA, Small Interfering | 1 | 2018 | 2188 | 0.100 |
Why?
|
Drug Therapy | 1 | 2012 | 195 | 0.100 |
Why?
|
Feces | 1 | 2015 | 799 | 0.100 |
Why?
|
Zoxazolamine | 1 | 2011 | 2 | 0.100 |
Why?
|
Cytochrome P450 Family 2 | 1 | 2011 | 11 | 0.100 |
Why?
|
Epigenesis, Genetic | 1 | 2019 | 1430 | 0.100 |
Why?
|
Steroid Hydroxylases | 1 | 2011 | 38 | 0.100 |
Why?
|
Arylsulfotransferase | 1 | 2011 | 19 | 0.100 |
Why?
|
Metabolic Detoxication, Phase I | 1 | 2011 | 10 | 0.100 |
Why?
|
Metabolic Detoxication, Phase II | 1 | 2011 | 17 | 0.100 |
Why?
|
Midazolam | 1 | 2011 | 72 | 0.090 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 80 | 0.090 |
Why?
|
Promoter Regions, Genetic | 1 | 2018 | 3031 | 0.090 |
Why?
|
Humans | 12 | 2021 | 262697 | 0.090 |
Why?
|
Communicable Diseases | 1 | 2012 | 205 | 0.090 |
Why?
|
Thienamycins | 1 | 2009 | 23 | 0.090 |
Why?
|
Immunoblotting | 1 | 2011 | 870 | 0.080 |
Why?
|
beta-Lactam Resistance | 1 | 2009 | 47 | 0.080 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 2008 | 33 | 0.080 |
Why?
|
Chemokines, CC | 1 | 2008 | 35 | 0.080 |
Why?
|
NF-kappa B p50 Subunit | 1 | 2008 | 55 | 0.080 |
Why?
|
Selection, Genetic | 1 | 2009 | 180 | 0.080 |
Why?
|
Kupffer Cells | 1 | 2008 | 40 | 0.080 |
Why?
|
Interleukin-1beta | 1 | 2010 | 294 | 0.080 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2008 | 140 | 0.080 |
Why?
|
Tissue Distribution | 2 | 2020 | 874 | 0.080 |
Why?
|
Sleep | 1 | 2011 | 427 | 0.070 |
Why?
|
Arthritis, Rheumatoid | 1 | 2012 | 447 | 0.070 |
Why?
|
Pseudomonas aeruginosa | 1 | 2009 | 239 | 0.070 |
Why?
|
Chemokines | 1 | 2008 | 291 | 0.070 |
Why?
|
Non-alcoholic Fatty Liver Disease | 1 | 2012 | 434 | 0.070 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2006 | 605 | 0.070 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 14707 | 0.070 |
Why?
|
Serine | 2 | 2006 | 379 | 0.070 |
Why?
|
Amino Acid Substitution | 2 | 2006 | 641 | 0.060 |
Why?
|
Transcription Factors | 1 | 2019 | 5246 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 3561 | 0.060 |
Why?
|
Interleukin-1 | 1 | 2006 | 465 | 0.060 |
Why?
|
Protein Kinases | 1 | 2008 | 871 | 0.060 |
Why?
|
NF-kappa B | 1 | 2011 | 1558 | 0.060 |
Why?
|
RNA Polymerase III | 1 | 2004 | 44 | 0.060 |
Why?
|
Oogenesis | 1 | 2004 | 69 | 0.060 |
Why?
|
Casein Kinase II | 1 | 2004 | 60 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 1055 | 0.060 |
Why?
|
Binding Sites | 2 | 2006 | 2125 | 0.050 |
Why?
|
Mutation, Missense | 1 | 2007 | 1164 | 0.050 |
Why?
|
Oocytes | 1 | 2004 | 409 | 0.050 |
Why?
|
Eukaryotic Initiation Factor-4E | 1 | 2021 | 94 | 0.050 |
Why?
|
Mice, Knockout | 1 | 2011 | 5669 | 0.050 |
Why?
|
Neoplasms | 2 | 2020 | 15585 | 0.050 |
Why?
|
Esterases | 1 | 2020 | 19 | 0.050 |
Why?
|
Bile | 1 | 2020 | 82 | 0.040 |
Why?
|
Caco-2 Cells | 1 | 2020 | 161 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2015 | 3570 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2015 | 4897 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2012 | 2220 | 0.040 |
Why?
|
Immunization | 1 | 2021 | 363 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2004 | 2831 | 0.040 |
Why?
|
Rats, Wistar | 1 | 2019 | 575 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 3057 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2021 | 2352 | 0.030 |
Why?
|
Transcription, Genetic | 1 | 2004 | 3077 | 0.030 |
Why?
|
Pharmacogenetics | 1 | 2017 | 257 | 0.030 |
Why?
|
Phosphorylation | 1 | 2004 | 4839 | 0.030 |
Why?
|
Female | 5 | 2020 | 143767 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2019 | 15958 | 0.030 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1377 | 0.020 |
Why?
|
Middle Aged | 2 | 2019 | 87462 | 0.020 |
Why?
|
Rats | 1 | 2019 | 6121 | 0.020 |
Why?
|
Colony Count, Microbial | 1 | 2009 | 149 | 0.020 |
Why?
|
Pseudomonas Infections | 1 | 2009 | 158 | 0.020 |
Why?
|
Aged | 1 | 2012 | 71287 | 0.020 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2006 | 316 | 0.020 |
Why?
|
Adult | 2 | 2019 | 78789 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 1546 | 0.010 |
Why?
|
Base Sequence | 1 | 2006 | 4775 | 0.010 |
Why?
|
Cell Line | 1 | 2006 | 5001 | 0.010 |
Why?
|
Lung | 1 | 2009 | 3172 | 0.010 |
Why?
|
Survival Analysis | 1 | 2009 | 9149 | 0.010 |
Why?
|
DNA | 1 | 2006 | 2672 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2019 | 33142 | 0.010 |
Why?
|
Models, Biological | 1 | 2006 | 3130 | 0.010 |
Why?
|
Child | 1 | 2017 | 29575 | 0.010 |
Why?
|